Global Idiopathic Pulmonary Fibrosis Market Report 2024

Idiopathic Pulmonary Fibrosis Global Market Report 2024 – By Drug Type (Nintedanib, Pirfenidone, Other Drug Types), By Mode Of Action (Antifibrotic Agents, Tyrosine Kinase Inhibitors, Other Modes of Action), By Route Of Administration (Oral, Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Providers), By End Users (Hospitals and Clinics, Other End Users) – Market Size, Trends, And Global Forecast 2024-2033

Idiopathic Pulmonary Fibrosis Global Market Report 2024

Starting Price : $5000.00 | Pages : | Published : January 2024 | Delivery Time: 2-3 business days | Format : pdf

Purchase Options
Request Sample
Request For Discount
FAQs
Customise Your Report
Request For Proposal
Request For Regional Data

Need assistance or more information before the purchase?

Enquire Before Buying
Idiopathic Pulmonary Fibrosis Global Market Report 2024

Proud Members Of

checkslacipN checkaoirsN checkscipN
Description Table Of Contents Tables & Figures Market Insights Related Reports

Idiopathic Pulmonary Fibrosis Market Definition And Segments

Idiopathic pulmonary fibrosis (IPF) is a lung disease characterized by the gradual and continuous deterioration of the tissue encompassing the air sacs, known as alveoli, in the lungs. This condition leads to the accumulation of scar tissue (fibrosis) within the lungs, impeding the efficient transportation of oxygen into the bloodstream.

The main drug types in idiopathic pulmonary fibrosis include nintedanib, pirfenidone, and others. Nintedanib is a medication prescribed for the treatment of specific lung conditions, such as idiopathic pulmonary fibrosis (IPF), an interstitial lung disease with a progressive phenotype, and interstitial lung disease associated with systemic sclerosis. The various modes of action include antifibrotic agents, tyrosine kinase inhibitors, and others with various routes of administration such as oral and parenteral. The various distribution channels include hospital pharmacies, retail pharmacies, and online for the various end users, including hospitals, clinics, and others.

The idiopathic pulmonary fibrosis market covered in this report is segmented –

1) By Drug Type: Nintedanib, Pirfenidone, Other Drug Types

2) By Mode Of Action: Antifibrotic Agents, Tyrosine Kinase Inhibitors, Other Modes of Action

3) By Route Of Administration: Oral, Parenteral

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Providers

5) By End Users: Hospitals and Clinics, Other End Users

The idiopathic pulmonary fibrosis market size has grown strongly in recent years. It will grow from $3.89 billion in 2023 to $4.13 billion in 2024 at a compound annual growth rate (CAGR) of 6.0%. The growth in the historic period can be attributed to increasing aging population, limited treatment options, rising disease awareness, healthcare infrastructure development.

The idiopathic pulmonary fibrosis market size is expected to see strong growth in the next few years. It will grow to $5.24 billion in 2028 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to expanded research and development, precision medicine approach, increasing disease incidence, advancements in biomarker development, government initiatives and funding. Major trends in the forecast period include advancements in diagnostic techniques, emergence of targeted therapies, telemedicine and remote monitoring, combination therapies, advancements in lung transplantation.

Surge In Fibrotic Diseases Propels Growth Of Idiopathic Pulmonary Fibrosis Market

The rise in the prevalence of fibrotic disease is expected to drive the growth of the idiopathic pulmonary fibrosis market going forward. Fibrotic diseases, also known as fibrosis, refer to a group of medical conditions characterized by the excessive formation and accumulation of fibrous connective tissue in various organs or tissues in the body. Idiopathic pulmonary fibrosis drugs help reduce lung fibrosis and inflammation by targeting multiple signaling pathways involved in fibrosis. For instance, in December 2022, according to the American Lung Association, a US-based lung association, there were around 207,000 people affected in the United States and approximately 58,000 new cases of idiopathic pulmonary fibrosis diagnosed each year, which is more common in men than women and mainly affects people over 50 years of age. Therefore, the rise in the prevalence of fibrotic disease drives the idiopathic pulmonary fibrosis market.

Growing Geriatric Population Fuels Expansion Of Idiopathic Pulmonary Fibrosis Market

An increasing geriatric population is expected to boost the growth of the idiopathic pulmonary fibrosis market going forward. The geriatric population refers to the elderly or senior citizens within a given society or population. Aging is associated with structural and functional changes in the lungs, making older individuals more susceptible to respiratory diseases such as IPF. This age-related vulnerability contributes to the overall demand for IPF treatments. For instance, in October 2022, according to the data released by the World Trade Organization, a US-based international organization, the proportion of the population aged 60 and up increased from 1 billion to 1.4 billion in 2021. By 2050, the world’s population of adults aged 60 and up will have doubled (to 2.1 billion). The number of people aged 80 or more is predicted to reach 426 million. Therefore, the increasing geriatric population is driving the growth of the idiopathic pulmonary fibrosis market.

Major companies operating in the idiopathic pulmonary fibrosis market report are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Sanofi S.A., Gilead Sciences Inc., Toray Industries Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Biogen Inc., Sun Pharmaceutical Industries Limited, Shionogi and Co. Ltd., Cipla Inc., Zydus Lifesciences Ltd., Chong Kun Dang Pharmaceutical Corp., Kyorin Pharmaceutical Co. Ltd., Galapagos NV, Veracyte Inc., Genentech Inc., FibroGen Inc., GNI Group Ltd., Pliant Therapeutics Inc., Pulmatrix Inc., Galimedix Therapeutics Inc., Avalyn Pharma Inc., MediciNova Inc., Liminal BioSciences Inc., Beijing Continent Pharmaceuticals Company, Galecto Inc.

Product Innovations Expanding Access And Affordability For Patients In The Idiopathic Pulmonary Fibrosis Market

Product innovation is a key trend gaining popularity in the idiopathic pulmonary fibrosis market. Major companies operating in the idiopathic pulmonary fibrosis market focus on developing innovative products to strengthen their position and gain a competitive advantage. For instance, in May 2022, Sandoz, a Switzerland-based company that manufactures generic and biosimilar medicines, launched a generic version of pirfenidone, which is the first AB-rated equivalent to Genentech's Esbriet, aimed at treating individuals suffering from idiopathic pulmonary fibrosis (IPF). This orally administered prescription medication is now accessible to patients through specialty pharmacies, and eligible patients can benefit from a USD 0 co-pay program.

Groundbreaking Anti-Fibrotic Small-Molecule Inhibitor Paving The Way In Idiopathic Pulmonary Fibrosis Treatment

Major companies operating in the idiopathic pulmonary fibrosis (IPF) market are focusing on innovative products, such as anti-fibrotic small-molecule inhibitors, to sustain their position in the market. Anti-fibrotic small-molecule inhibitors refer to a type of pharmaceutical compound designed to target and inhibit the fibrotic processes in the body. For instance, in June 2023, Insilico Medicine, a US-based clinical-stage biotechnology company using generative artificial intelligence (AI), announced the initiation of Phase II clinical trials for INS018_055, the world’s first anti-fibrotic small molecule inhibitor designed through generative AI. This milestone marks the first dose administered to patients in the trial, which is a randomized, double-blind, placebo-controlled study aimed at evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of a 12-week oral dosage of INS018_055 in subjects with idiopathic pulmonary fibrosis (IPF). This innovative approach leverages AI in drug discovery, showcasing a potential advancement in the treatment of idiopathic pulmonary fibrosis (IPF) diseases.

AbbVie Inc. Expands Immunology Portfolio With Acquisition Of DJs Antibodies Ltd.

In October 2022, AbbVie Inc., a US-based pharmaceutical company, acquired DJS Antibodies Ltd. for an undisclosed amount. With this acquisition, AbbVie aims to provide new capabilities to enhance its current antibody research endeavors, the potential to increase its immunology portfolio, and a solid foundation for extended research efforts in the dynamic bioscience hub. DJS Antibodies Ltd. is a UK-based biotechnology company that treats idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases.

North America was the largest region in the idiopathic pulmonary fibrosis market in 2023. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the idiopathic pulmonary fibrosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the idiopathic pulmonary fibrosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The idiopathic pulmonary fibrosis (IPF) market consists of sales of anti-inflammatory, MAPK inhibitors, autotoxin inhibitors and corticosteroids. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The idiopathic pulmonary fibrosis market research report is one of a series of new reports from The Business Research Company that provides idiopathic pulmonary fibrosis market statistics, including idiopathic pulmonary fibrosis industry global market size, regional shares, competitors with idiopathic pulmonary fibrosis market share, detailed idiopathic pulmonary fibrosis market segments, market trends, and opportunities, and any further data you may need to thrive in the idiopathic pulmonary fibrosis industry. This idiopathic pulmonary fibrosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Idiopathic Pulmonary Fibrosis Market Report Scope
Report AttributeDetails
Market Size Value In 2024 $4.13 billion
Revenue Forecast In 2033 $5.24 billion
Growth Rate CAGR of 6.2% from 2024 to 2033
Base Year For Estimation 2023
Actual Estimates/Historical Data 2018-2023
Forecast Period 2024 - 2028 - 2033
Market Representation Revenue in USD Billion and CAGR from 2024 to 2033
Segments Covered 1) By Drug Type: Nintedanib, Pirfenidone, Other Drug Types
2) By Mode Of Action: Antifibrotic Agents, Tyrosine Kinase Inhibitors, Other Modes of Action
3) By Route Of Administration: Oral, Parenteral
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Providers
5) By End Users: Hospitals and Clinics, Other End Users
Regional Scope Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Country Scope Australia; China; India; Indonesia; Japan; South Korea; Bangladesh; Thailand; Vietnam; Malaysia; Singapore; Philippines; Hong Kong; New Zealand; USA; Canada; Mexico; Brazil; Chile; Argentina; Colombia; Peru; France; Germany; UK; Austria; Belgium; Denmark; Finland; Ireland; Italy; Netherlands; Norway; Portugal; Spain; Sweden; Switzerland; Russia; Czech Republic; Poland; Romania; Ukraine; Saudi Arabia; Israel; Iran; Turkey; UAE; Egypt; Nigeria; South Africa
Key Companies Profiled F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Novartis AG; Bristol-Myers Squibb Company; AstraZeneca PLC; Sanofi S.A.; Gilead Sciences Inc.; Toray Industries Inc.; Boehringer Ingelheim International GmbH; Viatris Inc.; Biogen Inc.; Sun Pharmaceutical Industries Limited; Shionogi and Co. Ltd.; Cipla Inc.; Zydus Lifesciences Ltd.; Chong Kun Dang Pharmaceutical Corp.; Kyorin Pharmaceutical Co. Ltd.; Galapagos NV; Veracyte Inc.; Genentech Inc.; FibroGen Inc.; GNI Group Ltd.; Pliant Therapeutics Inc.; Pulmatrix Inc.; Galimedix Therapeutics Inc.; Avalyn Pharma Inc.; MediciNova Inc.; Liminal BioSciences Inc.; Beijing Continent Pharmaceuticals Company; Galecto Inc.
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. Idiopathic Pulmonary Fibrosis Market Characteristics

    3. Idiopathic Pulmonary Fibrosis Market Trends And Strategies

    4. Idiopathic Pulmonary Fibrosis Market - Macro Economic Scenario

    4.1. Impact Of High Inflation On The Market

    4.2. Ukraine-Russia War Impact On The Market

    4.3. COVID-19 Impact On The Market

    5. Global Idiopathic Pulmonary Fibrosis Market Size and Growth

    5.1. Global Idiopathic Pulmonary Fibrosis Market Drivers and Restraints

    5.1.1. Drivers Of The Market

    5.1.2. Restraints Of The Market

    5.2. Global Idiopathic Pulmonary Fibrosis Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)

    5.3. Global Idiopathic Pulmonary Fibrosis Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

    6. Idiopathic Pulmonary Fibrosis Market Segmentation

    6.1. Global Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Nintedanib

    Pirfenidone

    Other Drug Types

    6.2. Global Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Antifibrotic Agents

    Tyrosine Kinase Inhibitors

    Other Modes of Action

    6.3. Global Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Oral

    Parenteral

    6.4. Global Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Hospital Pharmacies

    Retail Pharmacies

    Online Providers

    6.5. Global Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Hospitals and Clinics

    Other End Users

    7. Idiopathic Pulmonary Fibrosis Market Regional And Country Analysis

    7.1. Global Idiopathic Pulmonary Fibrosis Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    7.2. Global Idiopathic Pulmonary Fibrosis Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8. Asia-Pacific Idiopathic Pulmonary Fibrosis Market

    8.1. Asia-Pacific Idiopathic Pulmonary Fibrosis Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.3. Asia-Pacific Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.4. Asia-Pacific Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    9. China Idiopathic Pulmonary Fibrosis Market

    9.1. China Idiopathic Pulmonary Fibrosis Market Overview

    9.2. China Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.3. China Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.4. China Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    10. India Idiopathic Pulmonary Fibrosis Market

    10.1. India Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.2. India Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.3. India Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11. Japan Idiopathic Pulmonary Fibrosis Market

    11.1. Japan Idiopathic Pulmonary Fibrosis Market Overview

    11.2. Japan Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.3. Japan Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.4. Japan Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12. Australia Idiopathic Pulmonary Fibrosis Market

    12.1. Australia Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.2. Australia Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.3. Australia Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13. Indonesia Idiopathic Pulmonary Fibrosis Market

    13.1. Indonesia Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.2. Indonesia Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.3. Indonesia Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14. South Korea Idiopathic Pulmonary Fibrosis Market

    14.1. South Korea Idiopathic Pulmonary Fibrosis Market Overview

    14.2. South Korea Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.3. South Korea Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.4. South Korea Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15. Western Europe Idiopathic Pulmonary Fibrosis Market

    15.1. Western Europe Idiopathic Pulmonary Fibrosis Market Overview

    15.2. Western Europe Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.3. Western Europe Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.4. Western Europe Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16. UK Idiopathic Pulmonary Fibrosis Market

    16.1. UK Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.2. UK Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.3. UK Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17. Germany Idiopathic Pulmonary Fibrosis Market

    17.1. Germany Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.2. Germany Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.3. Germany Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18. France Idiopathic Pulmonary Fibrosis Market

    18.5. France Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.6. France Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.7. France Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19. Italy Idiopathic Pulmonary Fibrosis Market

    19.9. Italy Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.10. Italy Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.11. Italy Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20. Spain Idiopathic Pulmonary Fibrosis Market

    20.13. Spain Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.14. Spain Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.15. Spain Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21. Eastern Europe Idiopathic Pulmonary Fibrosis Market

    21.1. Eastern Europe Idiopathic Pulmonary Fibrosis Market Overview

    21.2. Eastern Europe Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.3. Eastern Europe Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.4. Eastern Europe Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22. Russia Idiopathic Pulmonary Fibrosis Market

    22.1. Russia Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.2. Russia Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.3. Russia Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23. North America Idiopathic Pulmonary Fibrosis Market

    23.1. North America Idiopathic Pulmonary Fibrosis Market Overview

    23.2. North America Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.3. North America Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.4. North America Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24. USA Idiopathic Pulmonary Fibrosis Market

    24.1. USA Idiopathic Pulmonary Fibrosis Market Overview

    24.2. USA Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.3. USA Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.4. USA Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25. Canada Idiopathic Pulmonary Fibrosis Market

    25.1. Canada Idiopathic Pulmonary Fibrosis Market Overview

    25.2. Canada Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.3. Canada Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.4. Canada Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26. South America Idiopathic Pulmonary Fibrosis Market

    26.1. South America Idiopathic Pulmonary Fibrosis Market Overview

    26.2. South America Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.3. South America Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.4. South America Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27. Brazil Idiopathic Pulmonary Fibrosis Market

    27.1. Brazil Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.2. Brazil Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.3. Brazil Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28. Middle East Idiopathic Pulmonary Fibrosis Market

    28.1. Middle East Idiopathic Pulmonary Fibrosis Market Overview

    28.2. Middle East Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.3. Middle East Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.4. Middle East Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29. Africa Idiopathic Pulmonary Fibrosis Market

    29.1. Africa Idiopathic Pulmonary Fibrosis Market Overview

    29.2. Africa Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.3. Africa Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.4. Africa Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    30. Idiopathic Pulmonary Fibrosis Market Competitive Landscape And Company Profiles

    30.1. Idiopathic Pulmonary Fibrosis Market Competitive Landscape

    30.2. Idiopathic Pulmonary Fibrosis Market Company Profiles

    30.2.1. F. Hoffmann-La Roche Ltd.

    30.2.1.1. Overview

    30.2.1.2. Products and Services

    30.2.1.3. Strategy

    30.2.1.4. Financial Performance

    30.2.2. Merck & Co. Inc.

    30.2.2.1. Overview

    30.2.2.2. Products and Services

    30.2.2.3. Strategy

    30.2.2.4. Financial Performance

    30.2.3. Novartis AG

    30.2.3.1. Overview

    30.2.3.2. Products and Services

    30.2.3.3. Strategy

    30.2.3.4. Financial Performance

    30.2.4. Bristol-Myers Squibb Company

    30.2.4.1. Overview

    30.2.4.2. Products and Services

    30.2.4.3. Strategy

    30.2.4.4. Financial Performance

    30.2.5. AstraZeneca PLC

    30.2.5.1. Overview

    30.2.5.2. Products and Services

    30.2.5.3. Strategy

    30.2.5.4. Financial Performance

    31. Idiopathic Pulmonary Fibrosis Market Other Major And Innovative Companies

    31.1. Sanofi S.A.

    31.2. Gilead Sciences Inc.

    31.3. Toray Industries Inc.

    31.4. Boehringer Ingelheim International GmbH

    31.5. Viatris Inc.

    31.6. Biogen Inc.

    31.7. Sun Pharmaceutical Industries Limited

    31.8. Shionogi and Co. Ltd.

    31.9. Cipla Inc.

    31.10. Zydus Lifesciences Ltd.

    31.11. Chong Kun Dang Pharmaceutical Corp.

    31.12. Kyorin Pharmaceutical Co. Ltd.

    31.13. Galapagos NV

    31.14. Veracyte Inc.

    31.15. Genentech Inc.

    32. Global Idiopathic Pulmonary Fibrosis Market Competitive Benchmarking

    33. Global Idiopathic Pulmonary Fibrosis Market Competitive Dashboard

    34. Key Mergers And Acquisitions In The Idiopathic Pulmonary Fibrosis Market

    35. Idiopathic Pulmonary Fibrosis Market Future Outlook and Potential Analysis

    35.1 Idiopathic Pulmonary Fibrosis Market In 2028 - Countries Offering Most New Opportunities

    35.2 Idiopathic Pulmonary Fibrosis Market In 2028 - Segments Offering Most New Opportunities

    35.3 Idiopathic Pulmonary Fibrosis Market In 2028 - Growth Strategies

    35.3.1 Market Trend Based Strategies

    35.3.2 Competitor Strategies

    36. Appendix

    36.1. Abbreviations

    36.2. Currencies

    36.3. Historic And Forecast Inflation Rates

    36.4. Research Inquiries

    36.5. The Business Research Company

    36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Table 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Table 3: Global Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 4: Global Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 5: Global Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 6: Global Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 7: Global Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 8: Global Idiopathic Pulmonary Fibrosis Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 9: Global Idiopathic Pulmonary Fibrosis Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 10: Asia-Pacific, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 11: Asia-Pacific, Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 12: Asia-Pacific, Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 13: China, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 14: China, Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 15: China, Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 16: India, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 17: India, Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 18: India, Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 19: Japan, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 20: Japan, Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 21: Japan, Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 22: Australia, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 23: Australia, Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 24: Australia, Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 25: Indonesia, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 26: Indonesia, Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 27: Indonesia, Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 28: South Korea, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 29: South Korea, Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 30: South Korea, Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 31: Western Europe, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 32: Western Europe, Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 33: Western Europe, Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 34: UK, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 35: UK, Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 36: UK, Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 37: Germany, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 38: Germany, Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 39: Germany, Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 40: France, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 41: France, Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 42: France, Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 43: Italy, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 44: Italy, Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 45: Italy, Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 46: Spain, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 47: Spain, Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 48: Spain, Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 49: Eastern Europe, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 50: Eastern Europe, Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 51: Eastern Europe, Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 52: Russia, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 53: Russia, Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 54: Russia, Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 55: North America, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 56: North America, Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 57: North America, Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 58: USA, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 59: USA, Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 60: USA, Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 61: Canada, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 62: Canada, Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 63: Canada, Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 64: South America, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 65: South America, Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 66: South America, Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 67: Brazil, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 68: Brazil, Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 69: Brazil, Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 70: Middle East, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 71: Middle East, Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 72: Middle East, Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 73: Africa, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 74: Africa, Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 75: Africa, Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 76: F. Hoffmann-La Roche Ltd. Financial Performance
  • Table 77: Merck & Co. Inc. Financial Performance
  • Table 78: Novartis AG Financial Performance
  • Table 79: Bristol-Myers Squibb Company Financial Performance
  • Table 80: AstraZeneca PLC Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Figure 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Figure 3: Global Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 4: Global Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 5: Global Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 6: Global Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 7: Global Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 8: Global Idiopathic Pulmonary Fibrosis Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 9: Global Idiopathic Pulmonary Fibrosis Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 10: Asia-Pacific, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 11: Asia-Pacific, Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 12: Asia-Pacific, Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 13: China, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 14: China, Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 15: China, Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 16: India, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 17: India, Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 18: India, Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 19: Japan, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 20: Japan, Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 21: Japan, Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 22: Australia, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 23: Australia, Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 24: Australia, Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 25: Indonesia, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 26: Indonesia, Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 27: Indonesia, Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 28: South Korea, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 29: South Korea, Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 30: South Korea, Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 31: Western Europe, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 32: Western Europe, Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 33: Western Europe, Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 34: UK, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 35: UK, Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 36: UK, Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 37: Germany, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 38: Germany, Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 39: Germany, Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 40: France, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 41: France, Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 42: France, Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 43: Italy, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 44: Italy, Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 45: Italy, Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 46: Spain, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 47: Spain, Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 48: Spain, Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 49: Eastern Europe, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 50: Eastern Europe, Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 51: Eastern Europe, Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 52: Russia, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 53: Russia, Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 54: Russia, Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 55: North America, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 56: North America, Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 57: North America, Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 58: USA, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 59: USA, Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 60: USA, Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 61: Canada, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 62: Canada, Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 63: Canada, Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 64: South America, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 65: South America, Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 66: South America, Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 67: Brazil, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 68: Brazil, Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 69: Brazil, Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 70: Middle East, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 71: Middle East, Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 72: Middle East, Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 73: Africa, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 74: Africa, Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 75: Africa, Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 76: F. Hoffmann-La Roche Ltd. Financial Performance
  • Figure 77: Merck & Co. Inc. Financial Performance
  • Figure 78: Novartis AG Financial Performance
  • Figure 79: Bristol-Myers Squibb Company Financial Performance
  • Figure 80: AstraZeneca PLC Financial Performance
Forecasting Till 2030: Opportunities And Strategies In The Global Value Based Care Payment Market – Includes Value Based Care Payment Market Analysis
Read More
How Will The Nuclear Medicine Market Grow In 2022?
Read More
What Is The Pediatric Imaging Market Overview In 2022?
Read More
Latest Healthcare Technology Management Market Growth Study 2022-2026 By The Business Research Company
Read More
The Business Research Company offers the hospital acquired infection control market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the multiplex assays market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the healthcare it consulting market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the renal biomarkers market research report 2022 with industry size, share, segments and market growth
Read More
Pulmonary Arterial Hypertension Global Market Report 2024 – By Drug Class (Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators), By Route of Administration (Oral, Intravenous/ subcutaneous, Inhalational), By Distribution channel (Retail, Online) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Overactive Bladder Treatment Global Market Report 2024 – By Diseases Type (Idiopathic Bladder Overactivity, Neurogenic Bladder Overactivity), By Therapy (Anticholinergics, Mirabegron, Neurostimulation, Intravesical Instillation, Other Therapies), By Distribution Channel (Hospital Pharmacies, Drug Stores And Retail Pharmacies, Online Providers) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Constipation Treatment Global Market Report 2024 – By Therapeutic Types (Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C (Guanylate Cyclase-C) Agonists, Other Therapeutics), By Disease Type (Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome With Constipation (IBS-C), Opioid-Induced Constipation (OIC)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Generic Musculoskeletal Disorders Drugs Global Market Report 2024 – By Treatment Type (Medication, Therapy, Surgery, Other Treatment Types), By Disorder Type (Osteoarthritis, Rheumatoid Arthritis, Spondylarthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Fibromyalgia, Other Disorder Types), By Route of Administration (Oral, Parenteral, Other Routes), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Drug Store, Online Pharmacy) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Tumor Necrosis Factor Inhibitor Drugs Global Market Report 2024 – By Product Type (Humira, Enbrel, Remicade, Simponi/Simponi Aria, Cimzia, Biosimilars ), By Route Of Administration (Subcutaneous Injection, Intravenous Injection ), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies ), By Application (Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, Crohn’s Disease, Ulcerative Colitis, Ankylosing Spondylitis, Juvenile Idiopathic Arthritis, Hidradenitis Suppurativa, Other Applications ) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Plasma Protein Therapeutics Global Market Report 2024 – By Product (Immunoglobulin, Albumin, Coagulation Factor, C1-esterase Inhibitors, Other Products), By Route Of Administration (Intravenous, Subcutaneous), By Applications (Primary Immunodeficiency Disorder (PID), Idiopathic Thrombocytopenic Purpura, Secondary Immunodeficiency, Hereditary Angioedema, Other Applications) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Immunoglobulins Global Market Report 2024 – By Product (IGG, IGA, IGM, IGE, IGD. ), By Mode Of Delivery (Intravenous Mode of Delivery, Subcutaneous Mode of Delivery), By Application (Hypogammaglobulinemia, Chronic Inflammatory demyelinating polyneuropathy (CIDP), Immunodeficiency Disease, Myasthenia Gravis, Idiopathic thrombocytopenic purpura (ITP), Other Applications) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Gastroparesis Global Market Report 2024 – By Treatment Modality (Medications, Dietary Modifications, Medical Devices, Other Therapies), By Gastroparesis Type (Idiopathic, Diabetic, Post- Surgical, Other Types), By Patient Demographics (Pediatric Gastroparesis, Adult Gastroparesis), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Other Distribution Channels), By End User (Hospitals And Clinics, Ambulatory Surgical Centers, Home Care Settings) – Market Size, Trends, And Global Forecast 2024-2033
View Report

Frequently Asked Questions

What is the definition of the idiopathic pulmonary fibrosis market?

Idiopathic pulmonary fibrosis (IPF) is a lung disease characterized by the gradual and continuous deterioration of the tissue encompassing the air sacs, known as alveoli, in the lungs. This condition leads to the accumulation of scar tissue (fibrosis) within the lungs, impeding the efficient transportation of oxygen into the bloodstream. For further insights on the idiopathic pulmonary fibrosis market, request a sample here

How will the idiopathic pulmonary fibrosis market drivers and restraints affect the idiopathic pulmonary fibrosis market dynamics? What forces will shape the idiopathic pulmonary fibrosis industry going forward?

The idiopathic pulmonary fibrosis market major growth driver - Surge In Fibrotic Diseases Propels Growth Of Idiopathic Pulmonary Fibrosis Market. For further insights on the idiopathic pulmonary fibrosis market, request a sample here

What is the forecast market size or the forecast market value of the idiopathic pulmonary fibrosis market?

The idiopathic pulmonary fibrosis market size has grown strongly in recent years. It will grow from $3.89 billion in 2023 to $4.13 billion in 2024 at a compound annual growth rate (CAGR) of 6.0%. The growth in the historic period can be attributed to increasing aging population, limited treatment options, rising disease awareness, healthcare infrastructure development. The idiopathic pulmonary fibrosis market size is expected to see strong growth in the next few years. It will grow to $5.24 billion in 2028 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to expanded research and development, precision medicine approach, increasing disease incidence, advancements in biomarker development, government initiatives and funding. Major trends in the forecast period include advancements in diagnostic techniques, emergence of targeted therapies, telemedicine and remote monitoring, combination therapies, advancements in lung transplantation. For further insights on the idiopathic pulmonary fibrosis market, request a sample here

How is the idiopathic pulmonary fibrosis market segmented?

The idiopathic pulmonary fibrosis market is segmented
1) By Drug Type: Nintedanib, Pirfenidone, Other Drug Types
2) By Mode Of Action: Antifibrotic Agents, Tyrosine Kinase Inhibitors, Other Modes of Action
3) By Route Of Administration: Oral, Parenteral
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Providers
5) By End Users: Hospitals and Clinics, Other End UsersFor further insights on the idiopathic pulmonary fibrosis market, request a sample here

Which region has the largest share of the idiopathic pulmonary fibrosis market? What are the other regions covered in the report?

North America was the largest region in the idiopathic pulmonary fibrosis market in 2023. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the idiopathic pulmonary fibrosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa For further insights on the idiopathic pulmonary fibrosis market, request a sample here.

Who are the major players in the idiopathic pulmonary fibrosis market?

Major companies operating in the idiopathic pulmonary fibrosis market report are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Sanofi S.A., Gilead Sciences Inc., Toray Industries Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Biogen Inc., Sun Pharmaceutical Industries Limited, Shionogi and Co. Ltd., Cipla Inc., Zydus Lifesciences Ltd., Chong Kun Dang Pharmaceutical Corp., Kyorin Pharmaceutical Co. Ltd., Galapagos NV, Veracyte Inc., Genentech Inc., FibroGen Inc., GNI Group Ltd., Pliant Therapeutics Inc., Pulmatrix Inc., Galimedix Therapeutics Inc., Avalyn Pharma Inc., MediciNova Inc., Liminal BioSciences Inc., Beijing Continent Pharmaceuticals Company, Galecto Inc. For further insights on the idiopathic pulmonary fibrosis market, request a sample here.

What are the key trends in the idiopathic pulmonary fibrosis market?

Major trend in the idiopathic pulmonary fibrosis market - Product Innovations Expanding Access And Affordability For Patients In The Idiopathic Pulmonary Fibrosis Market. For further insights on the idiopathic pulmonary fibrosis market, request a sample here.

What are the major opportunities in the idiopathic pulmonary fibrosis market? What are the strategies for the idiopathic pulmonary fibrosis market?

For detailed insights on the major opportunities and strategies in the idiopathic pulmonary fibrosis market, request a sample here.

How does the idiopathic pulmonary fibrosis market relate to the overall economy and other similar markets?

For detailed insights on idiopathic pulmonary fibrosis market's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the idiopathic pulmonary fibrosis industry?

For detailed insights on the mergers and acquisitions in the idiopathic pulmonary fibrosis industry, request a sample here.

What are the key dynamics influencing the idiopathic pulmonary fibrosis market growth? SWOT analysis of the idiopathic pulmonary fibrosis market.

For detailed insights on the key dynamics influencing the idiopathic pulmonary fibrosis market growth and SWOT analysis of the idiopathic pulmonary fibrosis industry, request a sample here.